LaurenceHBakerDO

Oncology • Ann Arbor, MI

Professor, Health Research & Policy, Stanford University Medical Center

Join to view full profile

Dr. Baker is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Baker's full profile

Already have an account?

Office
1500 E Medical Center Dr
Fl
Ann Arbor, MI 48109
Phone+1 734-647-8902

Education & Training

Detroit Medical Center/Wayne State UniversityFellowship, Hematology and Medical Oncology, 1970 - 1972
Michigan Hospital and Medical CenterResidency, Internal Medicine, 1967 - 1969
Ascension Genesys HospitalInternship, Internal Medicine, 1966 - 1967
Des Moines University College of Osteopathic MedicineClass of 1966

Certifications & Licensure

MI State License 1965 - 2025
FL State License 1970 - 1979

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Fellow (FASCO) American Society of Clinical Oncologists, 2010
America's Top Doctors Castle Connolly, 2002-2007
America's Top Doctors for Cancer Castle Connolly, 2005-2006
Redbook Magazine: Top Breast Cancer Doctors Castle Connolly, 2001
Join now to see all

Clinical Trials

Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Start of enrollment: 1996 Apr 01
Completed
Phase 3
S0715: Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, II, or IIIA Breast Cancer Undergoing Chemo Start of enrollment: 2009 Sep 01
Completed
Phase 3
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer Start of enrollment: 2011 Nov 01
Completed
Not Applicable
S0927:Omega3-Fatty Acid Supp in Treating Muscle&Bone Pain&Stiffness in Pts W/Stg I,II,III Brst Canc Rec'v Hormone Thpy Start of enrollment: 2012 Feb 01
Completed
Phase 3
S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride Start of enrollment: 2011 Nov 15
Completed
Join now to see all

Publications & Presentations

PubMed

3 citations
Hyper-Dependence on NHEJ Enables Synergy between DNA-PK Inhibitors and Low-Dose Doxorubicin in Leiomyosarcoma.
Adrian Marino-Enriquez, Jan Philipp Novotny, Doga C Gulhan, Isabella Klooster, Antuan V Tran
Clinical Cancer Research. 2023-12-15
16 citations
Relationships between highly recurrent tumor suppressor alterations in 489 leiomyosarcomas.
Inga-Marie Schaefer, Meijun Z. Lundberg, Elizabeth G Demicco, Joanna Przybyl, Magdalena Matusiak
Cancer. 2021-03-31
Cancer Survivorship—Considering Mindsets—Reply
Laurence H. Baker, Erin Peregrine Antalis, Denise K. Reinke
JAMA Oncology. 2020-09-01

Press Mentions

How Will the Vertical Merger Guidelines Apply to Healthcare?November 4th, 2020
In Memoriam: Charles A. Coltman, 1930 to 2018March 12th, 2019
Capitol Hill Briefing: Consolidation in Health Care Likely to ContinueJanuary 10th, 2016
Join now to see all

Grant Support

Southwest Oncology Group Treatment GrantNational Cancer Institute2010–2012
Southwest Oncology Group BiorepositoryNational Cancer Institute2011
CCOP Research Base, Pcpt/Pcpt Ltfu, And Select ProgramsNational Cancer Institute2008–2011
Tumor Banking For The Southwest Oncology GroupNational Cancer Institute2005–2011
Southwest Oncology Group - Operations OfficeNational Cancer Institute2005–2009
Southwest Oncology GroupNational Cancer Institute1995–2009
Interim SWOG Committee Renewals (Breast, Head &Neck, Leukemia)National Cancer Institute2007
Foreign Accrual For SWOG 2006 Load U10ca32102National Cancer Institute2006
SWOG - Foreign Accrual Under UmiNational Cancer Institute2005
Imatinib Mesylate In Patients With Malignancy With Skeletal MetastasisNational Center For Research Resources2004–2005
Molecular Diagnosis Of SarcomasNational Cancer Institute2002
Pilot--Connective Tissue OncologyNational Cancer Institute2001–2002
Phase II Trial Of Ifosfamide, Doxorubicin &G-Csf In Soft Tissue SarcomasNational Center For Research Resources2000–2002
Phase II Study Of Tailored Dose Docetaxel In Metastatic Breast CancerNational Center For Research Resources2000–2002
Phase II Study Of Docetaxel &Herceptin In Metastatic Breast CancerNational Center For Research Resources2000–2002
Chemotherapy With Doxorubicin And Docetaxel In Operable Stage I Breast CancerNational Center For Research Resources1999–2002
NSABP Breast Cancer Prevention TrialNational Center For Research Resources1996–2000
Core--Clinical Trials Support FacilityNational Cancer Institute1996–2000
Clinical Oncology Research Career DevelopmentNational Cancer Institute1993–1996
Provide Cancer Center SupportNational Cancer Institute1994
Developmental Therapeutics Of Anticancer AgentsNational Cancer Institute1994
Developmental Therapeutics Of New Solid Tumor AnticancerNational Cancer Institute1989–1993
Cancer Center Support GrantNational Cancer Institute1988–1993
Biomedical Research SupportNational Center For Research Resources1992
Southwest Oncology GroupNational Cancer Institute1985–1991